Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma

Fig. 5

Undifferentiated pleomorphic sarcoma (UPS) Probabilistic Target Inhibition Map (PTIM)-guided resistance abrogation experiments. Values in the center of PTIM blocks represent expected scaled sensitivity following inhibition of associated block targets. a Histology of PCB197 human UPS sample (20x magnification). b Histology of S1–12 canine UPS sample (20x magnification). c Abbreviated PTIM model for the pediatric preclinical testing initiative (PPTI) screen of PCB197 human UPS sample. d Abbreviated PTIM model built from the PPTI screen of S1–12 canine UPS sample. e Schematic of experimental design for resistance abrogation experiments. f Cellular regrowth of PCB197 human UPS sample over 100 days following treatment by single and multi-agent compounds in sequence and in combination. g Cellular regrowth of S1–12 canine UPS sample over 100 days following treatment by single and multi-agent compounds in sequence and in combination. Data in (f-g) is based on n = 4 replicate experiments

Back to article page